

Switching to CRISPR–Cas Systems from Uncultivated Microbes

https://marketpublishers.com/r/SC56A747F59EN.html

Date: August 2018 Pages: 15 Price: US\$ 1,250.00 (Single User License) ID: SC56A747F59EN

Abstracts

REPORT HIGHLIGHTS

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is currently the biggest discovery in life science. As a precise gene editing tool, it has been widely used in many areas with a great potential to treat human diseases. While some CRISPR-based therapeutic studies are moving to clinical trials, CRISPR's therapeutic promise was brought into question when some issues were found that could become major obstacles in moving the great genome editing tools to the clinic.

While many groups are actively resolving these obstacles, the signi?cant challenges to minimize the immunological risks and avoid potential tumorgenicity have received more attention as big concerns for CRISPR-Cas therapeutics advancing toward the clinic. We believe it is timely to summarize and analyze the emerging immunological risk and potential tumorgenicity with the CRISPR-Cas systems, to predict how this exciting genome editing market will affect other related segments of the entire life science market in the next few years. We also hope our opinion could serve as a 'crowd crystal' on those discussions in response to the issues, and bring a better market environment for the technology to be sharpened and advanced into clinical applications.

REPORT INCLUDES:

Detailed understanding of the two major types of adaptive immunity to Cas9 proteins, i.e. humoral immunity and cell-mediated immunity

Comparison of in vivo and ex vivo CRISPR-Cas9 therapy and discussion about clinical safety and probability to enter human clinical trials



Coverage of technical areas such as protein engineering and metagenomic analysis as driving forces to new CRISPR-Cas system discovery

A look into the oncogenic risks by CRISPR-Cas9 genome editing and studies on the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back-on again



Contents

CHAPTER 1 CRISPR CAS GENOME EDITING: THERAPEUTIC OR THWARTED BY PREEXISTING HUMAN IMMUNITY?

Immunogenicity Risk Potential Solutions to Overcome Preexisting Immunity to Cas Proteins in Humans Oncogenicity Risk Potential Solutions to Overcome Oncogenicity Risk What Could Happen Next? Scientific Community Investors Regulatory Societies What to Expect in the Market?

CHAPTER 2 A NOTE FROM THE EDITOR

CHAPTER 3 ANALYST'S CREDENTIALS



I would like to order

Product name: Switching to CRISPR–Cas Systems from Uncultivated Microbes Product link: <u>https://marketpublishers.com/r/SC56A747F59EN.html</u>

> Price: US\$ 1,250.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/SC56A747F59EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970